Research ArticleOriginal Article
Open Access

Management and clinical outcomes of cardiogenic shock in King Abdulaziz University Hospital

A retrospective study

Hamza L. Fida, Mohammed A. Qutub, Alaa S. Algazzar, Abdulrahman S. AlDharrab, Terad A. Alnajjar, Anas M.A. Andijani and Ahmad M. Taiyeb
Saudi Medical Journal May 2023, 44 (5) 479-485; DOI: https://doi.org/10.15537/smj.2023.44.5.20220704

References

  1. 1.↵
    UpToDate. Definition, classification, etiology, and pathophysiology of shock in adults. [Updated 2022; Cited 2022 April 11;]. Available from: https://www.uptodate.com/contents/definition-classification-etiology-and-pathophysiology-of-shock-in-adults.
  2. 2.↵
    1. Reynolds HR,
    2. Hochman JS
    . Cardiogenic Shock. Circ 2008; 117: 686–897.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Thiele H,
    2. Zeymer U,
    3. Neumann FJ,
    4. Ferenc M,
    5. Olbrich HG,
    6. Hausleiter J, et al.
    Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012; 367: 1287–1296.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Kolte D,
    2. Khera S,
    3. Aronow WS,
    4. Mujib M,
    5. Palaniswamy C,
    6. Sule S, et al.
    Trends in Incidence, Management, and Outcomes of Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction in the United States. J Am Heart Assoc 2014; 3: e000590.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Shah M,
    2. Patnaik S,
    3. Patel B,
    4. Ram P,
    5. Garg L,
    6. Agarwal M, et al.
    Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Clin Res Cardiol 2018; 107: 287–303.
    OpenUrlPubMed
  6. 6.↵
    1. Wayangankar SA,
    2. Bangalore S,
    3. McCoy LA,
    4. Jneid H,
    5. Latif F,
    6. Karrowni W, et al.
    Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry. JACC Cardiovasc Interv 2016; 9: 341–351.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Berg DD,
    2. Bohula EA,
    3. Van Diepen S,
    4. Katz JN,
    5. Alviar CL,
    6. Baird-Zars VM, et al.
    Epidemiology of shock in contemporary cardiac intensive care units. Circ Cardiovasc Qual Outcomes 2019; 12: e005618.
    OpenUrlPubMed
  8. 8.↵
    1. Puymirat E,
    2. Fagon JY,
    3. Aegerter P,
    4. Diehl JL,
    5. Monnier A,
    6. Hauw-Berlemont C, et al.
    Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997–2012. Eur J Heart Fail 2017; 19: 192–200.
    OpenUrlPubMed
  9. 9.↵
    1. Schrage B,
    2. Weimann J,
    3. Dabboura S,
    4. Yan I,
    5. Hilal R,
    6. Becher PM, et al.
    Patient characteristics, treatment and outcome in non-ischemic vs. ischemic cardiogenic shock. J Clin Med 2020; 9: 931.
    OpenUrl
  10. 10.↵
    1. Van Diepen S,
    2. Katz JN,
    3. Albert NM,
    4. Henry TD,
    5. Jacobs AK,
    6. Kapur NK, et al.
    Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circ 2017; 136: e232–e68.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Ponikowski P,
    2. Voors AA,
    3. Anker SD,
    4. Bueno H,
    5. Cleland JG,
    6. Coats AJ, et al.
    2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. National Heart L
    , and Blood Institute. Low Blood Pressure. [Updated 2008; cited 2022 April 11]. Available from: https://www.nhlbi.nih.gov/health-topics/low-blood-pressure.
  13. 13.↵
    1. Awtry E,
    2. Jeon C,
    3. Ware MG
    , editors. Blueprints cardiology. Lippincott Williams & Wilkins; Philadelphia (USA): 2006.
  14. 14.↵
    1. Chesebro JH,
    2. Knatterud G,
    3. Roberts R,
    4. Borer J,
    5. Cohen LS,
    6. Dalen J, et al.
    Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circ 1987; 76: 142–154.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Levy B,
    2. Buzon J,
    3. Kimmoun A.
    Inotropes and vasopressors use in cardiogenic shock: when, which and how much? Curr Opin Crit Care 2019; 25: 384–390.
    OpenUrlCrossRef
  16. 16.↵
    1. Sakr Y,
    2. Reinhart K,
    3. Vincent JL,
    4. Sprung CL,
    5. Moreno R,
    6. Ranieri VM, et al.
    Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006; 34: 589–597.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Werdan K,
    2. Ruß M,
    3. Buerke M,
    4. Delle-Karth G,
    5. Geppert A,
    6. Schöndube FA.
    Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German- Austrian S3 Guideline. Dtsch Arztebl Int 2012; 109: 343.
    OpenUrlPubMed
  18. 18.↵
    1. Tariq S,
    2. Aronow WS.
    Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci 2015; 16: 29060–29068.
    OpenUrl
  19. 19.↵
    Cardiology ESo. Intraaortic balloon support for myocardial infarction with cardiogenic shock. [Updated 2013; cited 2022 April 11]. Available from: www.escardio.org/Guidelines/Recommended-Reading/Acute-Cardiovascular-Care/Intraaortic-balloon-support-for-myocardial-infarction-with-cardiogenic-shock.
  20. 20.↵
    1. Chu S,
    2. Sun P,
    3. Zhang Y,
    4. Li J,
    5. Liu L,
    6. Shi Y, et al.
    Intra-aortic balloon pump on in-hospital outcomes of cardiogenic shock: findings from a nationwide registry, China. ESC Heart Fail 2021. doi: 10.1002/ehf2.13479.
  21. 21.↵
    1. Léopold V,
    2. Gayat E,
    3. Pirracchio R,
    4. Spinar J,
    5. Parenica J,
    6. Tarvasmäki T, et al.
    Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med 2018; 44: 847–856.
    OpenUrl
  22. 22.↵
    1. Shabana A,
    2. Dholoo F,
    3. Banerjee P.
    Inotropic Agents and Vasopressors in the Treatment of Cardiogenic Shock. Curr Heart Fail Rep. 2020:1–11.
  23. 23.↵
    1. Schrage B,
    2. Westermann D.
    Mechanical circulatory support devices in cardiogenic shock and acute heart failure: current evidence. Curr Opin Crit Care 2019; 25: 391–396.
    OpenUrl
  24. 24.↵
    1. Udesen NL,
    2. Helgestad OK,
    3. Banke AB,
    4. Frederiksen PH,
    5. Josiassen J,
    6. Jensen LO, et al.
    Impact of concomitant vasoactive treatment and mechanical left ventricular unloading in a porcine model of profound cardiogenic shock. Crit Care 2020; 24: 1–10.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Sharma K,
    2. Charaniya R,
    3. Champaneri B,
    4. Bhatia S,
    5. Sharma V,
    6. Mansuri Z, et al.
    Assessing the hemodynamic impact of various inotropes combination in patients with cardiogenic shock with Non-ST elevation myocardial infarction–the ANAPHOR study. Indian Heart J 2021; 73: 572–576.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords